To prolong the PFS and overall survival (OS) of locally advanced or metastatic NSCLC with EGFR somatic mutations, laborious effects have been made continuously in combined models in recent years.10, 11, 12. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.